# CJC-1295 No DAC (Mod GRF 1-29): Evidence, Mechanism & Legal Status

> A clinical monograph on CJC-1295 without DAC (Mod GRF 1-29) — the short-acting, pulse-preserving GHRH analog. Solid preclinical pharmacology, no human RCT of the no-DAC molecule, and an unsettled 2026 legal status.

*Published 2026-06-30 · Updated 2026-07-01 · By Marcus Feld, PharmD, BCPS*

The short answer
CJC-1295 without DAC — properly **Mod GRF 1-29** — is a well-characterized GHRH-receptor agonist whose tetra-substituted chemistry and ~30-minute half-life produce a growth-hormone *pulse* rather than a plateau. Its GH-release pharmacology is proven in animals (**Grade C**); the popular human recovery, sleep and body-composition claims are anecdotal (**Grade D**), with no published human RCT of the no-DAC molecule. It is not FDA-approved, sits in an unsettled 2026 compounding limbo, and is prohibited in sport at all times under WADA.[2](https://peptidevox.com/#r2)[7](https://peptidevox.com/#r7)

CJC-1295 without DAC is one of the most-discussed peptides in recovery and longevity circles, almost always alongside ipamorelin. Its mechanism is elegant and genuinely documented; its human clinical case is thin. This monograph separates the proven pharmacology from the hyped human outcomes.[2](https://peptidevox.com/#r2)

*This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. CJC-1295 without DAC is not an FDA-approved drug; it is sold as a "research chemical not for human use" and is prohibited in sport. Dosing figures are reported strictly as seen in the published literature and anecdotal use — not as recommendations. Consult a licensed clinician before any health decision.*

## What is CJC-1295 without DAC and how does it work?

Native growth-hormone-releasing hormone signaling resides in its first 29 residues; GRF(1-29) (sermorelin) retains full GH-releasing activity but is destroyed within minutes in plasma, chiefly by dipeptidyl peptidase IV (DPP-IV) cleavage between residues Ala2 and Asp3, compounded by Asn8 deamidation and Met27 oxidation.[1](https://peptidevox.com/#r1) Mod GRF 1-29 hardens the peptide with four targeted substitutions, which is why it is also called "tetra-substituted GRF(1-29)."[1](https://peptidevox.com/#r1)[2](https://peptidevox.com/#r2)

  The four stabilizing substitutions in Mod GRF 1-29

    PositionSubstitutionPurpose

    2Ala → D-AlaBlocks DPP-IV N-terminal cleavage
    8Asn → GlnPrevents Asn→Asp deamidation / isomerization
    15Gly → AlaEnhances GHRH-receptor binding affinity
    27Met → LeuPrevents Met oxidation

There is a nomenclature trap worth flagging: some vendors mislabel plain sermorelin (lacking the four substitutions) as "Mod GRF 1-29," and the trade name "CJC-1295 without DAC" is itself a misnomer — the actual CJC-1295 molecule *is* the DAC bioconjugate, while the "no-DAC" product is simply the tetra-substituted backbone.[2](https://peptidevox.com/#r2)[14](https://peptidevox.com/#r14) Mechanistically, Mod GRF 1-29 binds the GHRH receptor on anterior-pituitary somatotrophs, a Gs-coupled receptor; activation stimulates adenylyl cyclase, cAMP and protein kinase A, driving synthesis and pulsatile release of growth hormone, which in turn raises hepatic IGF-1.[2](https://peptidevox.com/#r2)[12](https://peptidevox.com/#r12) Because it works upstream on the body's own somatotrophs, GH output remains subject to negative feedback from IGF-1 and somatostatin, so it cannot drive GH supraphysiologically the way injected recombinant GH can — a key safety distinction, and the reason a functioning pituitary is required for any GHRH agonist to work at all.

The half-life is the headline. The four substitutions extend plasma half-life from the under-10-minutes of native GRF(1-29)/sermorelin to roughly 30 minutes for Mod GRF 1-29 — long enough to provoke a meaningful GH pulse but short enough that GH returns to baseline between doses, preserving the natural pulsatile rhythm.[11](https://peptidevox.com/#r11) Full CJC-1295 instead adds a Drug Affinity Complex (a maleimidopropionic-acid/lysine moiety) that covalently binds circulating albumin, extending half-life to about 5.8 to 8.1 days and producing a multi-day "GH bleed" rather than a pulse.[2](https://peptidevox.com/#r2)[3](https://peptidevox.com/#r3) The functional trade-off is the entire rationale for the no-DAC form: the pulse keeps GH physiologically rhythmic (theoretically lower insulin-resistance and desensitization risk), whereas the DAC plateau is a continuous, non-pulsatile stimulus.[4](https://peptidevox.com/#r4) Like all GHRH-class peptides it is used parenterally (subcutaneous) in the literature; oral administration is futile because of gut proteolysis.[2](https://peptidevox.com/#r2)

## What is the evidence by indication?

**Bottom line up front:** there are no human RCTs of Mod GRF 1-29 (no-DAC) itself. The human-trial evidence in this family tested the DAC version or native GRF(1-29)/sermorelin/tesamorelin. Claims for the no-DAC molecule rest on rat and in-vitro pharmacology (Grade C) and extrapolation or anecdote (Grade D).

  CJC-1295 (no-DAC) evidence by claim

    ClaimBest evidenceGrade

    Acute GH / IGF-1 releaseRat in-vivo (~4× GH AUC over 2h) and cultured pituitary cells; porcine bioassay (11-13× potency)C (preclinical)
    Recovery, sleep quality, body compositionNo controlled human trials; extrapolation from GH physiology and user reportsD (anecdotal)
    Ipamorelin stack synergy (GH release)Dual-receptor GHRH+GHRP synergy is established pharmacology; the specific stack's clinical outcomes are notC (mechanism) / D (outcomes)
    DAC-version human GH/IGF-1 rise (context only)Human Phase 1; does NOT transfer as no-DAC efficacyA (but DAC, not no-DAC)

The acute GH-release data are solid — in animals. In male Sprague-Dawley rats and cultured rat anterior-pituitary cells the tetra-substituted backbone produced clear, dose-related GH secretion; subcutaneous administration in rats yielded roughly a 4-fold increase in GH area-under-the-curve over 2 hours versus native hGRF(1-29).[2](https://peptidevox.com/#r2) The earlier Hoffmann-La Roche work establishing the substitutions reported the stabilized analogs were about 3 times more potent in vitro and 11 to 13 times more potent in vivo (in pigs) than native GRF, with DPP-IV cleavage completely inhibited over 24 hours.[1](https://peptidevox.com/#r1) This is solid mechanistic proof that the molecule releases GH — in animals, not humans.

The popular human use cases are not in that tier. GH and slow-wave sleep are physiologically linked, and GH/IGF-1 support tissue repair and lipolysis, so the rationale for recovery, sleep and fat-loss benefit is biologically plausible — but there are no controlled human trials of Mod GRF 1-29 demonstrating those outcomes, and the claims are extrapolated from GH physiology, DAC-version pharmacology and user reports.[10](https://peptidevox.com/#r10) The ipamorelin stack rests on genuinely sound pharmacology: somatotrophs carry two independent receptors — the GHRH-R hit by Mod GRF 1-29 and the ghrelin receptor GHS-R1a hit by ipamorelin — and co-activating both produces a synergistic GH pulse, with ipamorelin favored for sparing cortisol, prolactin and ACTH.[12](https://peptidevox.com/#r12)[13](https://peptidevox.com/#r13) What is not established by trials is that the specific Mod GRF 1-29 plus ipamorelin stack improves any human clinical endpoint.

For context, the DAC and native-sequence human trials are real but do not transfer. The DAC version raised GH 2-to-10-fold and IGF-1 1.5-to-3-fold for days in healthy adults and was "safe and relatively well tolerated" in a Phase 1 study; details are registered through trial repositories such as [ClinicalTrials.gov](https://clinicaltrials.gov/).[3](https://peptidevox.com/#r3) A separate study showed pulsatility persisted despite continuous DAC stimulation in healthy men (trough GH up about 7.5-fold, mean 24-hour GH up about 46%, n≈21).[4](https://peptidevox.com/#r4) These are DAC data; they support the GHRH-agonist class concept but are not evidence for the short-acting no-DAC product's clinical efficacy.

Proven vs hyped
Proven: Mod GRF 1-29 releases GH in animals, and the GHRH-plus-GHRP synergy is real pharmacology. Hyped: that any of this translates into validated human recovery, sleep or body-composition outcomes for the short-acting no-DAC product. The molecule has never been tested in a published human RCT.[2](https://peptidevox.com/#r2)

## What doses appear in the literature?

Reported strictly as information, not a protocol. There is no validated human dose. Subcutaneous injection is the universal route in animal studies and anecdotal human use, with the peptide reconstituted from lyophilized powder using bacteriostatic water.[2](https://peptidevox.com/#r2)[11](https://peptidevox.com/#r11) Reported anecdotal human dosing is commonly cited as about 100 micrograms per injection (a "saturation dose" tied to the GHRH receptor), often once to a few times daily, frequently pre-sleep to align a GH pulse with nocturnal slow-wave sleep, and/or post-exercise, on an empty stomach to avoid blunting the pulse with food or insulin.[10](https://peptidevox.com/#r10) These figures are lay and anecdotal, not trial-derived. The common stack co-administers about 100 to 300 micrograms of ipamorelin in the same syringe, exploiting the GHRH-R plus GHS-R1a synergy; simultaneous (not staggered) dosing is the usual practice.[10](https://peptidevox.com/#r10) Because the half-life is only about 30 minutes, the dose is timed to a desired pulse and clears before the next — deliberately not maintaining a plateau, the opposite of how the once-weekly DAC version is used.[11](https://peptidevox.com/#r11) Product purity, identity and sterility in the research-chemical market are uncontrolled, which is itself a dosing-relevant safety problem.

## How safe is CJC-1295 without DAC?

Most reported adverse-effect data come from the DAC and class human studies plus anecdote, since no-DAC trials are absent. Commonly reported, generally mild events in GHRH-class use include injection-site reactions, facial flushing, transient headache and lightheadedness, water retention, and somnolence consistent with a GH pulse.[3](https://peptidevox.com/#r3) The DAC trials reported no serious adverse reactions at the doses tested — but that is short-term, supervised, DAC data and should not be read as a clean bill for chronic no-DAC use.[3](https://peptidevox.com/#r3)

The theoretical risks deserve to be taken seriously. Any sustained GH/IGF-1 elevation can be diabetogenic, so insulin resistance and impaired glucose tolerance are real concerns; the no-DAC pulse design theoretically mitigates this versus the DAC plateau, but that benefit is unproven in humans.[4](https://peptidevox.com/#r4) Because IGF-1 is mitogenic, chronically raising the GH/IGF-1 axis carries a theoretical risk of promoting occult or existing malignancy — the central precautionary concern for all GH secretagogues. Acromegaly-type effects are theoretical with chronic supraphysiologic use. Most concretely, the FDA specifically cited immunogenicity, impurities and limited clinical data when flagging this peptide class, and noted cardiac/heart-related reports associated with CJC-1295; unregulated research-chemical product compounds this risk.[5](https://peptidevox.com/#r5) Precautionary contraindications by GH/GHRH-class analogy include active or prior malignancy, pregnancy and lactation, uncontrolled diabetes or significant insulin resistance, active diabetic retinopathy, children and adolescents with open growth plates, and the critically ill.

## What is the FDA and WADA status in 2026?

CJC-1295 / Mod GRF 1-29 (no DAC) is not an FDA-approved drug; no NDA or BLA product exists, and the no-DAC form was never developed as a commercial pharmaceutical.[14](https://peptidevox.com/#r14) The compounding timeline is the fast-moving part. On September 29, 2023 the FDA placed roughly 19 peptide bulk substances — including CJC-1295 and ipamorelin — into interim 503A Category 2 ("may present significant safety risks"), citing immunogenicity, impurities, limited clinical data, plus heart-related reports for CJC-1295.[5](https://peptidevox.com/#r5) After 2024 litigation and a settlement that routed several peptides to the Pharmacy Compounding Advisory Committee, the FDA removed CJC-1295, ipamorelin and others from Category 2 in September 2024 — because the nominations were withdrawn, not because they were deemed safe.[5](https://peptidevox.com/#r5) The PCAC reviewed CJC-1295 (free base, acetate and DAC forms) on December 4, 2024 and did not recommend it for the 503A allowed bulks list.[5](https://peptidevox.com/#r5)

As of mid-2026 there is no FDA-approved or formally 503A-listed pathway for CJC-1295 / Mod GRF 1-29; PCAC recommendations are non-binding, and formal notice-and-comment rulemaking is required before any peptide is officially added to the allowed list.[6](https://peptidevox.com/#r6) Even reclassification would govern compounding legality only — it would not confer FDA approval, a validated indication, standardized dosing, or established benefit-risk.[6](https://peptidevox.com/#r6) For athletes the picture is unambiguous: CJC-1295 (and CJC-1293, sermorelin, tesamorelin) fall under WADA section S2.2 — Growth Hormone-Releasing Factors (GHRH and analogues) — prohibited at all times, in and out of competition, with ipamorelin and the GHRPs banned in the same section.[7](https://peptidevox.com/#r7)[8](https://peptidevox.com/#r8) WADA-accredited labs detect these peptides by LC-MS/MS.[9](https://peptidevox.com/#r9) It is not a DEA-scheduled controlled substance, but lack of scheduling does not make human use legal — it remains an unapproved drug.

**Bottom line.** CJC-1295 without DAC is a well-characterized GHRH-receptor agonist on paper — its tetra-substituted chemistry, ~30-minute half-life and pulse-preserving pharmacology are real and the legitimate reason it differs from full CJC-1295 with DAC and pairs logically with ipamorelin. But the human clinical case is thin: the molecule has been studied in animals and cells (Grade C), never in a published human RCT, and the headline human benefits are anecdotal extrapolations (Grade D). A measured view recognizes the elegant pulse-preserving design while insisting that elegant mechanism is not evidence of human benefit or safety. Regulatory facts here are current as of June 2026 and should be re-verified as the FDA compounding process advances.

---
Source: https://peptidevox.com/peptide-encyclopedia/cjc-1295-no-dac
Index: https://peptidevox.com/llms.txt · Full text: https://peptidevox.com/llms-full.txt